Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- PAINWeek
- 20.00 AANP
- 20.00 ACCME (All Other)
- 20.00 ACCME (MD/DO Only)
- 20.00 ACPE Pharmacy
- 20.00 ANCC
- 20.00 APA
$1,500.00
- LivDerm
- TME
- 0.25 AAPA Category I CME
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC
- 0.25 Participation
$0.00
In the United States, a rare disease is defined as a condition that affects fewer than 200,000 people in the US. While each rare disease may not seem to affect so many people, there may be as many as 7,000 rare diseases affecting an estimated 25-30 million Americans. More specifically, there over 1,000 rare skin diseases that are often an extreme burden to the collective many of patients affected by these conditions.
- LivDerm
- TME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.
- CMHC
- TME
$0.00
The increasing prevalence and impacts of overweight and obesity in patients with type 2 diabetes renders weight loss and weight loss maintenance an important part of treatment goals. In this 6-part webcast series, chaired by Robert H. Eckel, MD and Donna Ryan, MD, you will have a chance to hear from experts on the comprehensive management of obesity in patients with type 2 diabetes, including lifestyle modifications, the spectrum of pharmacotherapy and metabolic surgery, as well as how to practically apply these concepts to patient care.
- 0.50 ACCME (All Other)
- 0.50 ACCME (MD/DO Only)
- 0.50 ACPE Pharmacy
- 0.50 ANCC
$0.00
Huntington’s disease (HD) is a rare, progressive, genetic disorder resulting in a breakdown of nerve cells in the brain. Many types of clinicians are involved in the patient journey because HD affects movement, behavior, memory loss, impulse control, and the ability to do the simplest self-care activities.
This multimedia activity provides the collaborative care team of neurologists, psychiatrists, and allied healthcare providers with an improved understanding of the fundamentals of HD, its chronic burden, and how to treat patients accordingly. Hunting for Better Outcomes provides HCPs with an enhanced understanding of HD and tools for improving overall patient outcomes.
- CMHC
- 18.50 ABIM MOC and AMA PRA Category 1 Credit™
- 18.50 ACPE Pharmacy
- 18.50 AMA PRA Category 1 Credit™
- 18.50 ANCC
- 18.50 CDE
- 18.50 Participation
$0.00
Hundreds of practitioners gathered in Boston in October 2022 for the annual conference from Cardiometabolic Health Congress (CMHC). In the past 17 years, this medical conference has grown to be the biggest and most-anticipated event in evidence-based education for the diagnosis, treatment, and management of cardiometabolic diseases and risk factors. The On-Demand program includes all recordings from the general sessions of the live meeting; CME Symposia are posted as separate activities within the CMHC Educational Platform.
- 1.00 ACCME (All Other)
- 1.00 ACCME (MD/DO Only)
- 1.00 ACPE Pharmacy
- 1.00 ANCC
$0.00
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in females. The presence of comorbid psychiatric disorders, including depression and anxiety, and obsessive compulsive disorder, may mitigate symptoms and delay diagnosis. The short-term effects of undiagnosed or undertreated ADHD in females presents a range of academic and social problems during childhood and adolescence. This course will provide participants an overview of current diagnostic practices and emerging treatment for ADHD in females.
- TME
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
$0.00
Rett Syndrome is one of the most frequent causes of mental disability in females, with an estimated prevalence of 1 in 10,000 under the age of 12. It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.
- 0.25 ACCME (All Other)
- 0.25 ACCME (MD/DO Only)
- 0.25 ACPE Pharmacy
- 0.25 ANCC
$0.00
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare developmental epileptic encephalopathy caused by mutations in the CDLK5 gene. The CDKL5 gene provides instructions for making proteins essential for normal brain and neuron development. When there is a deficiency disorder, a hallmark symptom is seizures beginning at approximately 3 months of life.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients.